ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,103.69
-0.24%
Dow Jones
38,208.36
-0.46%
US Dollar vs MXN
17.0313
0.10%
Brent Oil
86.545
-0.85%
Bitcoin
61,246.96
-4.06%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Adma Biologics Inc (ADMA)

  7. Adma Biologics Inc (ADMA) Noticias

ADMA Adma Biologics Inc

6.60
0.02 (0.30%)
Pre Mercado
Última actualización: 08:16:48
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Adma Biologics Inc ADMA NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.02 0.30% 6.60 08:16:48
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
6.58
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
11/3/202415:05EDGAR2Form 8-K - Current report
11/3/202411:19EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
11/3/202406:00GLOBEADMA Biologics Announces FDA Approvals of Extended Room..
08/3/202420:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202415:05EDGAR2Form 8-K - Current report
05/3/202406:00GLOBEADMA Biologics to Participate in the Raymond James..
04/3/202420:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/2/202420:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/2/202420:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/2/202420:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/2/202420:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/2/202420:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/2/202415:21EDGAR2Form 8-K - Current report
28/2/202415:15EDGAR2Form 8-K - Current report
28/2/202415:10GLOBEADMA Biologics Announces CFO Transition
28/2/202415:05GLOBEADMA Biologics Announces Fourth Quarter and Full Year 2023..
27/2/202420:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202415:05GLOBEADMA Biologics to Report Fourth Quarter and Full Year 2023..
21/2/202407:00EDGAR2Form 8-K - Current report
21/2/202406:00GLOBEADMA Biologics Successfully Implements Innovative AI..
14/2/202410:50EDGAR2Form SC 13G - Statement of acquisition of beneficial..
08/1/202407:00EDGAR2Form 8-K - Current report
08/1/202406:30EDGAR2Form 8-K - Current report
08/1/202406:00GLOBEADMA Biologics Announces Preliminary Fourth Quarter 2023..
05/1/202420:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/12/202315:05GLOBEADMA Biologics Announces $135 Million Non-Dilutive..
12/12/202315:30EDGAR2Form 8-K - Current report
12/12/202306:00GLOBEADMA Biologics Announces FDA Approval for BIVIGAM® in the..
16/11/202315:31EDGAR2Form 8-K - Current report
16/11/202306:00GLOBEADMA BioCenters Receives FDA Approval for its Tenth Plasma..
08/11/202316:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202315:36EDGAR2Form 8-K - Current report
08/11/202315:05GLOBEADMA Biologics Announces Third Quarter 2023 Financial..
01/11/202306:00GLOBEADMA Biologics to Report Third Quarter 2023 Financial..
03/10/202320:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/10/202315:46EDGAR2Form 3 - Initial statement of beneficial ownership of..
02/10/202315:45EDGAR2Form 8-K - Current report
30/8/202315:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/8/202318:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/8/202319:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/8/202316:09EDGAR2Form 144 - Report of proposed sale of securities
18/8/202320:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/8/202311:58EDGAR2Form 144/A - Report of proposed sale of securities: [Amend]
17/8/202320:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/8/202319:47EDGAR2Form 144 - Report of proposed sale of securities
09/8/202316:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/8/202315:15EDGAR2Form 8-K - Current report
09/8/202315:05GLOBEADMA Biologics Announces Second Quarter 2023 Financial..
02/8/202306:00GLOBEADMA Biologics to Report Second Quarter 2023 Financial..
19/7/202306:30EDGAR2Form 8-K - Current report

Su Consulta Reciente

NASDAQ
ADMA
Adma Biologics
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados